Clinical study of focused ultrasound combined with immune checkpoint inhibitors (PD-1 / PD-L1 inhibitors) in the treatment of advanced malignant solid tumors

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043222

Enrollment

Unknown

Registered

2021-02-09

Start date

2021-02-08

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Malignant Solid Tumors

Interventions

Combined Treatment Group (phase 1):Focused Ultrasound

Combined Treatment Group (phase 2):Focused Ultrasound

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced malignant solid tumors who failed to receive standard treatment; 2. Subjects with ECoG score less than 2; 3. Subjects aged 18-85 years old; 4. Subjects whose estimated survival time is more than 3 months; 5. Subjects with at least one lesion suitable for focused ultrasound therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with worsening brain metastasis; 2. Patients with autoimmune diseases requiring long-term steroid use; 3. Patients with interstitial pneumonia; 4. Patients who have received allogeneic transplantation; 5. Patients with severe hepatic and renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Complications;Objective Response Rate (ORR);	—

Secondary

Measure	Time frame
Progression Free Survival (PFS);Overall Survival (OS);Tumor Markers;	—

Countries

China

Contacts

Public ContactWenzhi Chen

State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University

chenwz@cqmu.edu.cn+86 23-68485021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026